Search results
Results From The WOW.Com Content Network
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, [2] is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular ...
Shares of the medical device maker rose 1.5% in afternoon trading. The approval makes the device, branded Agent, the first drug-coated balloon catheter in the U.S. to treat coronary in-stent ...
Boston Scientific forecast a full-year profit on Wednesday that was largely ahead of analysts' estimates and said the U.S. health regulator has approved its heart device, sending the company's ...
These findings were reported to European Union authorities in 2009, and resulted in approval for marketing the device. A study of 300 patients is in progress for US approvals. [ 6 ] [ 11 ] Small nonrandomized early-phase studies primarily intended to show the feasibility of an entirely subcutaneous ICD were updated, combined and published in ...
Biocompatibles International plc was a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, [2] which was, in turn, acquired by Boston Scientific in 2019. [3] [4] Approved oncology products were supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut.
Adding to its growing list of electrophysiology (EP) products, Boston Scientific has gained approval from the Food and Drug Administration for its IntellaTip MiFi XP catheter, the company ...
On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...
The next day, Boston Scientific increased their bid to $25 billion, followed the next day by Johnson & Johnson increasing their bid to $24.2 billion. It was not until January 17 that Boston Scientific produced a new offer of $27.2 billion ($80 per share), with the help of Abbott Laboratories. Abbott agreed to purchase $1.4 billion of Boston ...